Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Ben Land-Maycock is an associate in the corporate practice group in the London office.

Mr. Land-Maycock advises clients on transactional matters including negotiated mergers and acquisitions, takeovers, IPOs and restructurings.

  • A NYSE-listed high tech manufacturing group on its acquisition of a UK-headquartered global manufacturing and distribution business.
  • Oxford Immunotec Global plc, a NASDAQ-listed UK plc, on its $100 million share repurchase program.
  • Tencent on its lead Series A investment into Everledger, a UK-based blockchain startup.
  • Merck on its €2.1 billion acquisition of Antelliq Group, a leader in digital animal identification, traceability and monitoring solutions. 
  • Ziylo Ltd and its selling shareholders on its sale to Novo Nordisk for a total consideration that may exceed $800 million.
  • Crescendo Biologics Limited on its $70 million Series B Financing.
  • Syncona Limited on its founding investments in SwanBio Therapeutics Limited and Orbit Biomedical Limited.
  • Pulmocide Limited on its $30 million Series B Financing.
  • A diagnostics company focused on immune-regulated conditions in a $40 million follow-on offering.
  • A private equity fund in relation to a €45,000,000 credit facility.